Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Galena Biopharma Inc (NASDAQ:GALE) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Galena Biopharma Inc (NASDAQ:GALE) shares after opening at $2.40on last trade day and at the end of the day closed at $2.22. Company price to sales ratio in past twelve months was calculated as 94.74 and price to cash ratio as 4.96. Galena Biopharma Inc (NASDAQ:GALE)showed a negative weekly performance of -23.97%.
Officials in Massachusetts have blocked sales of Zogenix, Inc. (NASDAQ:ZGNX) ‘s controversial but U.S.-approved painkiller Zohydro, prompting the drugmaker to criticize what it called an “unprecedented action.” Zogenix, Inc. (NASDAQ:ZGNX) shares fell -6.83% in last trading session and ended the day on $2.73. ZGNX return on assets ratio is recorded as -105.40%. Zogenix, Inc. (NASDAQ:ZGNX) yearly performance is 51.67%.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) refuted ‘false and misleading’ claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio’s public presentation of significant positive news about all of the Company’s programs. Feuerstein’s headline falsely claims that NW Bio’s CEO, Linda Powers, “disclosed problems” with the Company’s Phase III clinical trial. On the contrary, Ms. Powers announced entirely positive news about the Company’s Phase III trial as well as its other programs, and Ms. Powers emphasized in her presentation that prior claims by a commentator (i.e., Feuerstein) that there were problems with the Company’s Phase III trial were unfounded and wrong. Ms. Powers reiterated that the Phase III trial is progressing well, and further centers of excellence are joining the trial. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares moved down -7.71% in last trading session and was closed at $7.18, while trading in range of $6.80 – 7.45. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)year to date (YTD) performance is 90.45%.
Vical Incorporated (NASDAQ:VICL) researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Vical Incorporated (NASDAQ:VICL) weekly performance is -16.34%. On last trading day company shares ended up $1.28. Vical Incorporated (NASDAQ:VICL) distance from 50-day simple moving average (SMA50) is -11.17%. Analysts mean target price for the company is $3.23.
Leave a Reply